Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
77
VTVT Quote, Financials, Valuation and Earnings
Last price:
$37.18
Seasonality move
:
20.36%
Day range:
$36.09 - $37.99
52-week range:
$13.15 - $37.99
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
15,335.63x
P/B ratio:
2.09x
Volume:
17.5K
Avg. volume:
13.9K
1-year change:
170.37%
Market cap:
$147.7M
Revenue:
$1M
EPS (TTM):
-$3.32
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
VTVT
vTv Therapeutics, Inc.
|
-- | -$0.98 | -100% | -91.43% | $40.67 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
NNVC
NanoViricides, Inc.
|
-- | -$0.08 | -- | -42.49% | $6.50 |
|
OGEN
Oragenics, Inc.
|
-- | -- | -- | -- | $2.00 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
TOVX
Theriva Biologics, Inc.
|
-- | -$0.38 | -- | -94.42% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
VTVT
vTv Therapeutics, Inc.
|
$37.50 | $40.67 | $147.7M | -- | $0.00 | 0% | 15,335.63x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$4.57 | $0.85 | $575.9M | 7.68x | $0.80 | 0% | 8.88x |
|
NNVC
NanoViricides, Inc.
|
$1.20 | $6.50 | $21.6M | -- | $0.00 | 0% | -- |
|
OGEN
Oragenics, Inc.
|
$0.83 | $2.00 | $682.6K | -- | $0.00 | 0% | 0.53x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics, Inc.
|
$0.20 | $7.00 | $6.8M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
VTVT
vTv Therapeutics, Inc.
|
0.51% | 0.275 | 0.39% | 9.69x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
NNVC
NanoViricides, Inc.
|
-- | 0.464 | -- | 0.95x |
|
OGEN
Oragenics, Inc.
|
3.86% | -0.075 | 36.62% | 3.97x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
29.07% | -3.365 | 66.16% | 0.68x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
VTVT
vTv Therapeutics, Inc.
|
-$2K | -$10.7M | -123.38% | -124.41% | -26100% | -$4.8M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
NNVC
NanoViricides, Inc.
|
-$132.8K | -$1.8M | -92.29% | -92.29% | -- | -$1.7M |
|
OGEN
Oragenics, Inc.
|
-- | -$3.1M | -311.49% | -509.23% | -- | -$3M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
-$28K | -$4.4M | -148.18% | -171.04% | -- | -$4.3M |
vTv Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns VTVT or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -21376.47% compared to vTv Therapeutics, Inc.'s net margin of -255.85%. vTv Therapeutics, Inc.'s return on equity of -124.41% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital VTVTvTv Therapeutics, Inc.-- -$1.08 $70.9M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About VTVT or NBY?
vTv Therapeutics, Inc. has a consensus price target of $40.67, signalling upside risk potential of 8.45%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -81.4%. Given that vTv Therapeutics, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe vTv Therapeutics, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VTVTvTv Therapeutics, Inc.2 1 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is VTVT or NBY More Risky?
vTv Therapeutics, Inc. has a beta of 0.505, which suggesting that the stock is 49.48% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock VTVT or NBY?
vTv Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. vTv Therapeutics, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VTVT or NBY?
vTv Therapeutics, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. vTv Therapeutics, Inc.'s net income of -$10.3M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, vTv Therapeutics, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 7.68x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for vTv Therapeutics, Inc. is 15,335.63x versus 8.88x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VTVTvTv Therapeutics, Inc.15,335.63x -- -- -$10.3M NBYNovaBay Pharmaceuticals, Inc.8.88x 7.68x $521K -$1.3M
-
Which has Higher Returns VTVT or NNVC?
NanoViricides, Inc. has a net margin of -21376.47% compared to vTv Therapeutics, Inc.'s net margin of --. vTv Therapeutics, Inc.'s return on equity of -124.41% beat NanoViricides, Inc.'s return on equity of -92.29%.
Company Gross Margin Earnings Per Share Invested Capital VTVTvTv Therapeutics, Inc.-- -$1.08 $70.9M NNVCNanoViricides, Inc.-- -$0.10 $7.2M -
What do Analysts Say About VTVT or NNVC?
vTv Therapeutics, Inc. has a consensus price target of $40.67, signalling upside risk potential of 8.45%. On the other hand NanoViricides, Inc. has an analysts' consensus of $6.50 which suggests that it could grow by 441.67%. Given that NanoViricides, Inc. has higher upside potential than vTv Therapeutics, Inc., analysts believe NanoViricides, Inc. is more attractive than vTv Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VTVTvTv Therapeutics, Inc.2 1 0 NNVCNanoViricides, Inc.1 0 0 -
Is VTVT or NNVC More Risky?
vTv Therapeutics, Inc. has a beta of 0.505, which suggesting that the stock is 49.48% less volatile than S&P 500. In comparison NanoViricides, Inc. has a beta of 1.158, suggesting its more volatile than the S&P 500 by 15.816%.
-
Which is a Better Dividend Stock VTVT or NNVC?
vTv Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NanoViricides, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. vTv Therapeutics, Inc. pays -- of its earnings as a dividend. NanoViricides, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VTVT or NNVC?
vTv Therapeutics, Inc. quarterly revenues are --, which are smaller than NanoViricides, Inc. quarterly revenues of --. vTv Therapeutics, Inc.'s net income of -$10.3M is lower than NanoViricides, Inc.'s net income of -$1.8M. Notably, vTv Therapeutics, Inc.'s price-to-earnings ratio is -- while NanoViricides, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for vTv Therapeutics, Inc. is 15,335.63x versus -- for NanoViricides, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VTVTvTv Therapeutics, Inc.15,335.63x -- -- -$10.3M NNVCNanoViricides, Inc.-- -- -- -$1.8M
-
Which has Higher Returns VTVT or OGEN?
Oragenics, Inc. has a net margin of -21376.47% compared to vTv Therapeutics, Inc.'s net margin of --. vTv Therapeutics, Inc.'s return on equity of -124.41% beat Oragenics, Inc.'s return on equity of -509.23%.
Company Gross Margin Earnings Per Share Invested Capital VTVTvTv Therapeutics, Inc.-- -$1.08 $70.9M OGENOragenics, Inc.-- -$1.96 $10.2M -
What do Analysts Say About VTVT or OGEN?
vTv Therapeutics, Inc. has a consensus price target of $40.67, signalling upside risk potential of 8.45%. On the other hand Oragenics, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 141.11%. Given that Oragenics, Inc. has higher upside potential than vTv Therapeutics, Inc., analysts believe Oragenics, Inc. is more attractive than vTv Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VTVTvTv Therapeutics, Inc.2 1 0 OGENOragenics, Inc.1 0 0 -
Is VTVT or OGEN More Risky?
vTv Therapeutics, Inc. has a beta of 0.505, which suggesting that the stock is 49.48% less volatile than S&P 500. In comparison Oragenics, Inc. has a beta of 0.922, suggesting its less volatile than the S&P 500 by 7.781%.
-
Which is a Better Dividend Stock VTVT or OGEN?
vTv Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. vTv Therapeutics, Inc. pays -- of its earnings as a dividend. Oragenics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VTVT or OGEN?
vTv Therapeutics, Inc. quarterly revenues are --, which are smaller than Oragenics, Inc. quarterly revenues of --. vTv Therapeutics, Inc.'s net income of -$10.3M is lower than Oragenics, Inc.'s net income of -$3.1M. Notably, vTv Therapeutics, Inc.'s price-to-earnings ratio is -- while Oragenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for vTv Therapeutics, Inc. is 15,335.63x versus 0.53x for Oragenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VTVTvTv Therapeutics, Inc.15,335.63x -- -- -$10.3M OGENOragenics, Inc.0.53x -- -- -$3.1M
-
Which has Higher Returns VTVT or PTN?
Palatin Technologies has a net margin of -21376.47% compared to vTv Therapeutics, Inc.'s net margin of --. vTv Therapeutics, Inc.'s return on equity of -124.41% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital VTVTvTv Therapeutics, Inc.-- -$1.08 $70.9M PTNPalatin Technologies-- -- -- -
What do Analysts Say About VTVT or PTN?
vTv Therapeutics, Inc. has a consensus price target of $40.67, signalling upside risk potential of 8.45%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than vTv Therapeutics, Inc., analysts believe Palatin Technologies is more attractive than vTv Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VTVTvTv Therapeutics, Inc.2 1 0 PTNPalatin Technologies0 0 0 -
Is VTVT or PTN More Risky?
vTv Therapeutics, Inc. has a beta of 0.505, which suggesting that the stock is 49.48% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock VTVT or PTN?
vTv Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. vTv Therapeutics, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VTVT or PTN?
vTv Therapeutics, Inc. quarterly revenues are --, which are larger than Palatin Technologies quarterly revenues of --. vTv Therapeutics, Inc.'s net income of -$10.3M is higher than Palatin Technologies's net income of --. Notably, vTv Therapeutics, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for vTv Therapeutics, Inc. is 15,335.63x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VTVTvTv Therapeutics, Inc.15,335.63x -- -- -$10.3M PTNPalatin Technologies-- -- -- --
-
Which has Higher Returns VTVT or TOVX?
Theriva Biologics, Inc. has a net margin of -21376.47% compared to vTv Therapeutics, Inc.'s net margin of --. vTv Therapeutics, Inc.'s return on equity of -124.41% beat Theriva Biologics, Inc.'s return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital VTVTvTv Therapeutics, Inc.-- -$1.08 $70.9M TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M -
What do Analysts Say About VTVT or TOVX?
vTv Therapeutics, Inc. has a consensus price target of $40.67, signalling upside risk potential of 8.45%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3349.98%. Given that Theriva Biologics, Inc. has higher upside potential than vTv Therapeutics, Inc., analysts believe Theriva Biologics, Inc. is more attractive than vTv Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VTVTvTv Therapeutics, Inc.2 1 0 TOVXTheriva Biologics, Inc.1 1 0 -
Is VTVT or TOVX More Risky?
vTv Therapeutics, Inc. has a beta of 0.505, which suggesting that the stock is 49.48% less volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.
-
Which is a Better Dividend Stock VTVT or TOVX?
vTv Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. vTv Therapeutics, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VTVT or TOVX?
vTv Therapeutics, Inc. quarterly revenues are --, which are smaller than Theriva Biologics, Inc. quarterly revenues of --. vTv Therapeutics, Inc.'s net income of -$10.3M is lower than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, vTv Therapeutics, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for vTv Therapeutics, Inc. is 15,335.63x versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VTVTvTv Therapeutics, Inc.15,335.63x -- -- -$10.3M TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
85
HUT alert for Dec 24
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Buy
63
GPCR alert for Dec 24
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.
Sell
32
SMX alert for Dec 24
SMX (Security Matters) Plc [SMX] is down 8.94% over the past day.
